Mint Labs

QMENTA, Inc., originally founded as Mint Labs in April 2013, provides an AI-powered, cloud-based platform for medical image analysis, with a specific focus on neurological diseases. The company was established in Barcelona, Spain, by Dr. Vesna Prchkovska and Dr. Paulo Rodrigues, who met during their PhD studies and shared a vision to improve the diagnosis and treatment of brain disorders. Their backgrounds in neuroscience, biomedical engineering, and software development formed the foundation of the company's mission to address the challenges in neuroimaging for clinical trials and patient care.

The firm operates on a B2B model, primarily serving two market segments: clinical trials and clinical care. For clinical trials, which currently constitute the main revenue source, QMENTA offers a bundled price for the entire trial duration, covering a set number of patients and analyses. For clinical care settings like hospitals, the model is a fee-per-image-analysis. This dual approach targets pharmaceutical corporations, biotech companies, and healthcare providers, enabling them to manage, analyze, and derive insights from large-scale neuroimaging data. Clients can compliantly collect data, perform quality control, and utilize advanced biomarker analysis, which accelerates the development of new therapies.

The core of QMENTA's offering is its secure, HIPAA-compliant and FDA 510(k) cleared platform. This integrated system allows medical specialists to upload various medical images, which are then standardized and processed using a suite of AI-powered algorithms. A key feature is the creation of detailed 3D brain maps that help quantify the effects of treatments and characterize patients. The platform includes a marketplace of over 50 AI algorithms for analyzing features like brain connectivity, lesions, and tissue damage, assisting in diagnosis and prognosis. This centralizes data management and analysis, eliminating the need for disparate software and facilitating collaboration among researchers and clinicians worldwide.

Significant milestones include a major rebranding from Mint Labs to QMENTA in October 2017 to better reflect its focus on quality, quantification, and the brain. The company secured a $3.2M seed round in early 2017 and has received multiple grants. A pivotal achievement was receiving FDA 510(k) clearance in 2021 for its QMENTA Care Platform, allowing its use in clinical settings by qualified physicians. Co-founder Vesna Prchkovska was appointed CEO in February 2021, having previously served as COO, and was later recognized as a Gold Stevie Award winner for Female Entrepreneur of the Year.

Keywords: neuroimaging, medical image analysis, AI in healthcare, clinical trials, brain disease, neurological disorders, 3D brain mapping, cloud medical imaging, biomarker analysis, digital health, HealthTech, quantitative imaging, medical imaging platform, neuroinformatics, MRI analysis, drug discovery, DICOM, PACS integration, clinical decision support, medical software